Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.24 USD

55.24
4,909,215

+0.92 (1.69%)

Updated Nov 4, 2024 01:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Infinity (INFI) Q2 Loss Wider than Expected, View Intact

by Zacks Equity Research

Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.

    Arpita Dutt headshot

    Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals

    by Arpita Dutt

    Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.

      Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales

      by Zacks Equity Research

      Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.

        Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top

        by Zacks Equity Research

        Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.

          Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses

          by Zacks Equity Research

          Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.

            The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts

            by Zacks Equity Research

            The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts

              Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong

              by Zacks Equity Research

              Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.

                What's in the Cards for Celldex (CLDX) this Earnings Season?

                by Zacks Equity Research

                With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                  Arpita Dutt headshot

                  Key FDA Events to Watch Out for in Aug 2017

                  by Arpita Dutt

                  Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More

                    by Arpita Dutt

                    Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.

                      Seattle Genetics (SGEN) Q2 Loss Narrower than Expected

                      by Zacks Equity Research

                      Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.

                        Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches

                        by Zacks Equity Research

                        Roche Holdings (RHHBY) delivered an impressive performance in 1H17 driven by new drug launches.

                          Company News For July 28, 2017

                          by Zacks Equity Research

                          Companies In The News Are: PG,MA,BMY,BUD

                            Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View

                            by Zacks Equity Research

                            Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.

                              Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

                              by Zacks Equity Research

                              Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

                                Indrajit Bandyopadhyay headshot

                                Bristol-Myers (BMY) Q2 Earnings Beats Estimates

                                by Indrajit Bandyopadhyay

                                Bristol-Myers (BMY) reports second-quarter results beating both earnings and sales estimates.

                                  AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

                                  by Zacks Equity Research

                                  AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.

                                    Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

                                    by Zacks Equity Research

                                    Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

                                      What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

                                      by Zacks Equity Research

                                      Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

                                        Sweta Killa headshot

                                        Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

                                        by Sweta Killa

                                        Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

                                          What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

                                          by Zacks Equity Research

                                          Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

                                            by Arpita Dutt

                                            Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

                                              Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

                                              by Zacks Equity Research

                                              Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

                                                Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

                                                by Zacks Equity Research

                                                Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

                                                  Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

                                                  by Zacks Equity Research

                                                  Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.